Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

September 20, 2013

Study Completion Date

December 26, 2013

Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
BIOLOGICAL

Romiplostim

Romiplostim will be administered weekly by subcutaneous injection

Trial Locations (48)

2031

Research Site, Randwick

4102

Research Site, Woolloongabba

5000

Research Site, Adelaide

15006

Research Site, A Coruña

19140

Research Site, Philadelphia

20817

Research Site, Bethesda

20900

Research Site, Monza (MB)

21000

Research Site, Dijon

24641

Research Site, Richlands

28100

Research Site, Novara

28222

Research Site, Majadahonda

28602

Research Site, Hickory

28922

Research Site, Alcorcón

29010

Research Site, Málaga

29414

Research Site, Charleston

31059

Research Site, Toulouse

33435

Research Site, Boynton Beach

33604

Research Site, Pessac

36100

Research Site, Vicenza

40479

Research Site, Düsseldorf

47166

Research Site, Duisburg

50674

Research Site, Cologne

70124

Research Site, Bari

71013

Research Site, San Giovanni Rotondo FG

80131

Research Site, Napoli

92801

Research Site, Anaheim

92868

Research Site, Orange

93143

Research Site, Bondy

94010

Research Site, Créteil

95124

Research Site, Catania

625 00

Research Site, Brno

708 52

Research Site, Ostrava-Poruba

100 34

Research Site, Prague

128 08

Research Site, Prague

128 20

Research Site, Prague

01307

Research Site, Dresden

00161

Research Site, Roma

80-952

Research Site, Gdansk

40-032

Research Site, Katowice

20-080

Research Site, Lublin

61-505

Research Site, Poznan

50-367

Research Site, Wroclaw

08035

Research Site, Barcelona

CV2 2DX

Research Site, Coventry

LS9 7TF

Research Site, Leeds

E1 2ES

Research Site, London

SW17 0QT

Research Site, London

OX3 9DU

Research Site, Oxford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY